PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-0.71
Negative D/E while Biotechnology median is 0.00. Seth Klarman would scrutinize balance sheet quality and look for restructuring potential.
-21.29
Net cash position versus Biotechnology median net debt of 1.74. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
-1.69
Negative coverage while Biotechnology median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
0.10
Current ratio below 50% of Biotechnology median of 2.02. Michael Burry would check for immediate refinancing needs.
No Data
No Data available this quarter, please select a different quarter.